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Neurology, perhaps more than any other
field of medicine, relies on a close associ-
ation between clinical phenotype and
underlying pathology. This is certainly
the case for the neurodegenerative dis-
eases where despite advances in genetics
and biomarkers a careful clinical assess-
ment remains the key to accurate diagno-
sis. In this context, Alois Alzheimer’s
description of the association between
progressive cognitive decline centred on
episodic memory and the presence of
amyloid plaque and tau tangle pathology
remains central to our formulation of
Alzheimer’s disease—although his ori-
ginal case was highly atypical, being a
young woman now known to have an
autosomal dominantly inherited form of
the disease.1
A fundamental question that underlies
all neurodegenerative disorders is why
certain pathologies associate fairly reli-
ably with certain clinical phenotypes.
Seminal pathology studies in Alzheimer’s
disease showed that amyloid plaque and
tangle pathology spreads through the
brain in a fairly predictable sequence,
starting in the medial temporal lobe
before involving other neocortical struc-
tures;2 this sequential spread—particu-
larly of tau pathology—correlates broadly
with the typical progression of symp-
toms. More recently, the availability of
biomarkers has allowed for other aspects
of the pathological cascade to be assessed
in vivo. Cerebrospinal fluid allows for
measurement of brain-enriched proteins,
inflammation and synaptic dysfunction;
positron-emission tomography allows for
visualisation of abnormal deposits of
amyloid and tau, and patterns of glucose
metabolism; and MRI techniques allow
for quantification of neuronal cell loss
(atrophy), and for interrogation of struc-
tural and functional connectivity, perfu-
sion and tissue microstructure. Together,
these techniques are opening up ever
earlier and more accurate diagnosis,3 as
well as providing insights into the inter-
action between different pathological
processes. Thus, the pathology of
Alzheimer’s disease is emerging as a
much more dynamic process than previ-
ously thought, likely to include accumula-
tion of—and interaction between—
several different protein moieties, inflam-
mation, self-promoting propagation of
pathology through a vulnerable ‘default
mode’ network, perhaps via prion-like
spread, synaptic breakdown, neurochem-
ical loss and neuronal cell death, all of
which occur well before the emergence
of symptoms.
While amyloid plaques and neurofibril-
lary tangles are most commonly asso-
ciated with an amnestic syndrome,
individual patients inevitably have differ-
ent constellations and degrees of cogni-
tive symptomatology, with some having
sufficiently unusual phenotypes to be
considered as having distinct disease var-
iants.4 These include patients with prom-
inent dysexecutive or behavioural
problems (frontal Alzheimer’s disease),
those presenting with word-finding diffi-
culties and pauses in speech (logopenic
aphasia), with perhaps the most striking
clinical phenotype being those with
various combinations of cortical visual
dysfunction, apraxia and dyscalculia with
relative sparing of episodic memory (pos-
terior cortical atrophy). Beh et al5
provide a valuable clinical overview of
the posterior cortical atrophy syndrome,
with a particular focus on the often very
striking and distinctive visual phenomen-
ology these patients experience.
How can the same broad underlying
pathology be associated with such mark-
edly different clinical manifestations?
Aside from having very different initial
symptoms, there are several other notable
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differences between the posterior cortical atrophy and
amnestic forms of Alzheimer’s disease.6 Patients with
posterior cortical atrophy are usually (although not
exclusively) younger, typically with disease onset in
the 50s or 60s. While pathological studies show that
the extent and topography of amyloid deposition it is
not absolutely identical in amnestic and posterior cor-
tical atrophy-Alzheimer’s disease, amyloid burden as
measured using positron-emission tomography shows
global cortical deposition in both variants, in marked
contrast to the posterior neuronal loss and hypometa-
bolism typical of posterior cortical atrophy (figure 1).
There is also evidence for important similarities and
key differences in the pattern of network breakdown
in the different Alzheimer’s disease variants.7 Finally,
there may be genetic differences between posterior
cortical atrophy and amnestic Alzheimer’s disease,
with hints that despite their typically young age of
onset, patients with posterior cortical atrophy may be
less likely than expected to carry the most common
genetic risk for sporadic Alzheimer’s disease, an ApoE
E4 allele.8
Identifying common and discordant genetic (and
environmental) risk factors for posterior cortical
atrophy and typical Alzheimer’s disease, combined
with neuroimaging, cerebrospinal fluid and other bio-
markers, may provide fundamental insights into
Alzheimer’s disease pathogenesis. It is entirely plaus-
ible that different risk factors influence the rate,
timing and site of amyloid deposition; whether or
when amyloid deposition leads to neurodegeneration;
and which neuronal networks bear the brunt of the
disease, in turn influencing how pathology spreads
through the brain, and what symptoms predominate.
Scientific interest aside, neurologists should be alert to
the fact that Alzheimer’s disease can present with
unusual phenotypes, and that these are important to
recognise to allow prompt diagnosis and appropriate
treatment, support and guidance (eg, for posterior
cortical atrophy, see http://www.ucl.ac.uk/drc/
pcasupport). It is equally important not to overlook
the existence or emergence of impairments in visual
and other non-memory functions even in patients pre-
senting with amnestic Alzheimer’s disease, noting that
such deficits were found even in Alois Alzheimer’s
index case, whom he noted: ‘…holds the book in
such a way that one has the impression that she has a
loss in the right visual field’.9
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